Confirmed Myocarditis-Myositis Overlap Without Myasthenia Gravis: Evaluating for Triple M Syndrome Following Combined Enfortumab Vedotin and Pembrolizumab Therapy
Cureus · 24.09.2026
DOI: 10.7759/cureus.116849 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cureus, erschienen am 24.09.2026. Verfasst von Bryan Ashong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Anesthesia, University of South Florida Morsani College of Medicine, Tampa, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
A 64-year-old male with Stage III urothelial carcinoma of the right ureter presented to the emergency department 3 weeks after a single cycle of combined enfortumab vedotin and pembrolizumab with chest tightness, neck weakness, drop head, and myalgias. Laboratory findings included markedly elevated high-sensitivity troponin I, creatine phosphokinase, lactate dehydrogenase, and transaminases. Electrocardiography showed anterolateral ST depression and left anterior fascicular block, which was new as compared to a prior tracing. He was managed in the cardiovascular intensive care unit. Cardiac catheterization revealed concurrent 90% mid-left anterior descending artery stenosis, treated with drug-eluting stent placement. Endomyocardial biopsy confirmed focal moderate lymphocytic myocarditis. Cardiac MRI demonstrated mildly reduced biventricular function and a non-ischemic pattern of late gadolinium enhancement consistent with myocarditis sequelae. Given the overlapping multisystem presentation, a multidisciplinary team (cardiology, neurology, and oncology) elected to treat with high-dose methylprednisolone (1 g QOD x 5 days), the guideline-recommended first-line therapy for ICI-associated myocarditis, and intravenous immunoglobulin (400 mg/kg QOD x 5 days), with biochemical improvement. IVIG was added given clinical concern for possible neuromuscular junction involvement in the setting of concurrent myositis and possible overlap syndrome, reflecting a precautionary approach to a potentially rapidly progressive presentation. Myasthenia gravis was considered but not confirmed: repeated neurological examinations demonstrated no fatigable weakness, and serology was negative for acetylcholine receptor binding and muscle-specific kinase antibodies. Both implicated agents were permanently discontinued. This case illustrates the spectrum and severity of multisystem immune-related toxicity from combined antibody-drug conjugate and immune checkpoint inhibitor therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Anesthesia, University of South Florida Morsani College of Medicine, Tampa, USA.
- Internal Medicine, Jawaharlal Nehru Medical College, Ajmer, IND.
Zitieren
APA
Ashong, B., & Ranga, Y. (2026). Confirmed Myocarditis-Myositis Overlap Without Myasthenia Gravis: Evaluating for Triple M Syndrome Following Combined Enfortumab Vedotin and Pembrolizumab Therapy. Cureus. https://doi.org/10.7759/cureus.116849
Vancouver
Ashong B, Ranga Y. Confirmed Myocarditis-Myositis Overlap Without Myasthenia Gravis: Evaluating for Triple M Syndrome Following Combined Enfortumab Vedotin and Pembrolizumab Therapy. Cureus. 2026. doi:10.7759/cureus.116849
BibTeX
@article{Ashong2026,
author = {Ashong, Bryan and Ranga, Yash},
title = {Confirmed Myocarditis-Myositis Overlap Without Myasthenia Gravis: Evaluating for Triple M Syndrome Following Combined Enfortumab Vedotin and Pembrolizumab Therapy},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.116849}
}
EUVIMED